References
- Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.
- Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel J, et al.. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.
- Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33–40.
- Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–80.
- Psaila B, Bussel J. Refractory idiopathic thrombocytopenic purpura: current strategies for investigation and management. A review of the treatment options in refractory ITP highlighting the potential role of the thrombopoietin agonists. Brit J Haematol. 2008:143;16–26.
- Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol. 2007:44;35–45.
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al.. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008:371;395–403.
- Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with ITP. Blood. 2009:113;2161–71.
- Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al.. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402.
- Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, et al.. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010:95;1167–75.
- Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al.. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.
- Newland A, Cervinék L, Eggermann J, Lefrere F, Kreuzbauer G. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim — four European case studies. Haematologica. 2011;96(2):98.